Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senores PharmaceuticalsNSE:SENORES +0.51%19 EV-to-EBIT is 34.46 as of Aug. 30, 2026, which is 26% above its 10-year median of 27.43. GuruFocus rates NSE:SENORES with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 685 Drug Manufacturers companies, Senores Pharmaceuticals ranks worse than 76.93% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Senores Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was ₹61,247 Mil.
Senores Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,993 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senores Pharmaceuticals EV-to-EBIT Related Terms
Senores Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SENORES vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senores Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Senores Pharmaceuticals's EV-to-EBIT falls into.
Senores Pharmaceuticals's current Enterprise Value is ₹68,663 Mil.
Senores Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,993 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senores Pharmaceuticals (NSE:SENORES) has a EV-to-EBIT of 34.46 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Senores Pharmaceuticals and its competitors. This is 26% above median its historical median of 27.43. Over the past decade, Senores Pharmaceuticals' EV-to-EBIT has ranged from 17.13 to 35.35. According to the industry distribution chart, Senores Pharmaceuticals ranks #527 out of 685 companies in the Drug Manufacturers industry, placing it in the top 76.9%.
Is Senores Pharmaceuticals' EV-to-EBIT too high?
Senores Pharmaceuticals' current EV-to-EBIT of 34.46 is 26% above median its 10-year median of 27.43. Over the past 10 years, this metric has ranged from a low of 17.13 to a high of 35.35. The Drug Manufacturers industry median EV-to-EBIT is 16.22. Senores Pharmaceuticals' value of 34.46 is 112.5% above this industry median. Based on the distribution chart, Senores Pharmaceuticals ranks #527 out of 685 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Senores Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #527 out of 685 companies for EV-to-EBIT. This places Senores Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 16.22. Senores Pharmaceuticals' value of 34.46 is 112.5% above this benchmark. Historically, Senores Pharmaceuticals' own EV-to-EBIT has ranged from 17.13 to 35.35 over the past decade. While the company's 10-year median is 27.43 vs. the industry median of 16.22, Senores Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.22, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senores Pharmaceuticals's current EV-to-EBIT of 34.46 is 112.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Senores Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current EV-to-EBIT is 34.46, which is 26% above median its own 10-year median of 27.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current EV-to-EBIT of 34.46. The current EV-to-EBIT is 34.46, which is 26% above median its 10-year median of 27.43 and 112.5% above the Drug Manufacturers industry median of 16.22. Senores Pharmaceuticals' overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current EV-to-EBIT is 34.46 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
19GF Score
Get the complete analysis for NSE:SENORES
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
